Taro Pharmaceutical Industries Ltd. (TARO)
(Delayed Data from NYSE)
$107.44 USD
+0.88 (0.83%)
Updated May 3, 2019 04:02 PM ET
After-Market: $107.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TARO]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Industry: Medical - Drugs
Sun Pharma Completes Buyout; Dropping Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Sun Finalizes Acquisition Price; Downgrading to Neutral With $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
Optimized Entry and Exit Levels for TARO 112223
Provider: Stock Traders Daily
Analyst: Research Department
Industry: Medical - Drugs
F2Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
F1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
Price Pressures Take Their Toll; Lowering PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Top-Line Beat, Bottom-Line Miss; F1Q23 Financials; Lowering PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
F2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Alchemee Acquired From Galderma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Another Revenue and Bottom-Line Miss; Lowering PT to $73
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Revenue Outlook Uncertain, But Downside Risk Seems Low; Reducing PT to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
Fiscal 1Q22 Results Yield Top-Line Beat, Bottom-Line Miss; Raising PT to $82
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Revenue In-Line, Bottom-Line Miss; Adjusting PT to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
F2Q21 Top- and Bottom-Line Beat; Modulating PT to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Substantial Top- and Bottom-Line Miss, Yet We Remain Optimistic on Long-Term Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Global Settlement Reached; Reiterate Buy; Reducing PT to $82
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Latest Price Collusion Complaint Shall Bear Close Watching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R